Yuan Y - Search Results

1

Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.

Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Yuan Y, et al. Value Health. 2008 Mar;11 Suppl 1:S11-22. doi: 10.1111/j.1524-4733.2008.00362.x. Value Health. 2008. PMID: 18387054 Free article.

2

Effects of ambulatory-care pharmacist consultation on mortality and hospitalization.

Yuan Y, Hay JW, McCombs JS. Yuan Y, et al. Am J Manag Care. 2003 Jan;9(1):45-56. Am J Manag Care. 2003. PMID: 12549814 Free article.

3

Development of a parametric simulation model for forecasting goal-oriented treatment outcomes.

Yuan Y, Chen RS, L'Italien G, Karaniewsky R. Yuan Y, et al. Value Health. 2004 Jul-Aug;7(4):482-9. doi: 10.1111/j.1524-4733.2004.74011.x. Value Health. 2004. PMID: 15449640 Free article.

4

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.

Iloeje UH, Yuan Y, L'italien G, Mauskopf J, Holmberg SD, Moorman AC, Wood KC, Moore RD. Iloeje UH, et al. Among authors: yuan y. HIV Med. 2005 Jan;6(1):37-44. doi: 10.1111/j.1468-1293.2005.00265.x. HIV Med. 2005. PMID: 15670251 Free article.

5

Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.

Yuan Y, L'italien G, Mukherjee J, Iloeje UH. Yuan Y, et al. HIV Med. 2006 Apr;7(3):156-62. doi: 10.1111/j.1468-1293.2006.00355.x. HIV Med. 2006. PMID: 16494629 Free article.

6

Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.

Yuan Y, Iloeje UH, Hay J, Saab S. Yuan Y, et al. J Manag Care Pharm. 2008 Jan-Feb;14(1):21-33. doi: 10.18553/jmcp.2008.14.1.21. J Manag Care Pharm. 2008. PMID: 18240879 Free PMC article.

7

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

Arnold E, Yuan Y, Iloeje U, Cook G. Arnold E, et al. Among authors: yuan y. Appl Health Econ Health Policy. 2008;6(4):231-46. doi: 10.1007/BF03256136. Appl Health Econ Health Policy. 2008. PMID: 19382822

8

Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.

Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Yuan Y, et al. J Med Econ. 2010 Mar;13(1):33-41. doi: 10.3111/13696990903508021. J Med Econ. 2010. PMID: 20001596 Free article.

9

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

Townsend R, McEwan P, Kim R, Yuan Y. Townsend R, et al. Among authors: yuan y. Value Health. 2011 Dec;14(8):1068-77. doi: 10.1016/j.jval.2011.06.006. Epub 2011 Aug 27. Value Health. 2011. PMID: 22152176 Free article. Review.

10

The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan.

Liu GG, DiBonaventura Md, Yuan Y, Wagner JS, L'Italien GJ, Langley P, Kamae I. Liu GG, et al. Among authors: yuan y. Value Health. 2012 Jan-Feb;15(1 Suppl):S65-71. doi: 10.1016/j.jval.2011.11.012. Value Health. 2012. PMID: 22265070 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,604 results

Search Page

Filters